专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

121. 发明申请

US20130005690A1 S-NITROSYLATION OF GLUCOSYLATING TOXINS AND USES THEREFOR 有权
标题翻译：葡萄球菌毒素的S-硝基化及其用途
公开(公告)号：US20130005690A1
公开(公告)日：2013-01-03
申请号：US13485801
申请日：2012-05-31
申请人： Tor C. Savidge , Jonathan Stamler
发明人： Tor C. Savidge , Jonathan Stamler
IPC分类号： A61K31/6615 , A61P31/04
CPC分类号： A61K39/08 , A61K31/198 , A61K31/21 , A61K31/6615 , A61K38/063 , A61K45/06 , Y02A50/469 , A61K2300/00
摘要： Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.
摘要翻译：本文提供了用于改善病理生理学半胱氨酸蛋白酶外毒素的方法，包括向所述个体施用有效剂量的S-亚硝酰化剂和磷酸肌醇或其类似物的步骤。

122. 发明申请

US20120316139A1 ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF 审中-公开
标题翻译：抗炎化合物及其用途
公开(公告)号：US20120316139A1
公开(公告)日：2012-12-13
申请号：US13559884
申请日：2012-07-27
申请人： Basil RIGAS
发明人： Basil RIGAS
IPC分类号： A61K31/661 , C07F9/6574 , A61K31/6615 , A61P29/00 , A61P9/00 , A61P25/28 , A61P25/00 , A61P37/00 , A61P35/00 , A61P9/12 , A61P19/04 , A61P11/08 , A61P11/02 , A61P35/02 , C07F9/09
CPC分类号： A61K31/6615 , A61K31/661 , C07F9/091 , C07F9/093 , C07F9/094 , C07F9/65742
摘要： Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also disclosed.
摘要翻译：公开了通式的化合物，其具有治疗与炎症相关疾病如癌症，神经变性和心血管疾病的活性。还公开了药物组合物和使用方法。

123. 发明授权

US08304394B2 Low side effect pharmaceutical composition containing isoniazid 有权
标题翻译：含有异烟肼的低副作用药物组合物
公开(公告)号：US08304394B2
公开(公告)日：2012-11-06
申请号：US13059929
申请日：2008-07-23
申请人： Yoapu Oliver Hu , Ton ho Young
发明人： Yoapu Oliver Hu , Ton ho Young
IPC分类号： A61K31/7048 , A61K31/4409 , A61K31/661 , A61K31/06
CPC分类号： A61K45/06 , A61K31/4409 , A61K31/6615 , A61K31/7048 , A61K2300/00
摘要： The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds. Said compound was selected from the following groups of compounds: Nordihydroguaiaretic acid, Trans-Cinnamaldehyde, Daidzein, Isovitexin, Kaempferol, disulfuram, β-Myrcene, Quercetin, (−)-Epigallocatechin-3-gallate, (+)-Limonene, Myricetin, Quercitrin, Luteolin-7-Glucoside, Morin, Neohesperidin, Hesperidin, Capillarisin, (−)-Epigallocatechin, Luteolin, Hyperoside, Ethyl Myristate, Tamarixetin, Phloretin, Baicalein, Rutin, Baicalin, Apigenin, Naringenin, Hesperetin, (+)-Epicatechin, (−)-Epicatechin-3-gallat, Isoliquritigenin, Silybin, Vitexin, Genistein, Isorhamnetin, gallic acid, Diosmin, 6-Gingerol, (+)-Taxifolin, Wongonin, Protocatechuic acid, (+)-Catechin, β-naphthoflavone, Embelin, Trans-Cinnamic acid, (−)-Epicatechin, Phloridzin, Puerarin, Umbelliferone, Brij 58, Brij 76, Brij 35, Tween 20, Tween 80, Tween 40, PEG 2000, PEG 400, Pluornic F68, and PEG 4000. The novel, low side-effect compound complex which contains pharmaceutically effective doses of isoniazid (INH), disulfuram (DSF) and/or a third compound, bis-nitrophenyl phosphate (BNPP) can reduce isoniazid (INH)-induced side effects, e.g. hepatotoxicity, etc.
摘要翻译：本发明的特征在于一种新颖的低副作用药物复合物，其包含药学有效剂量的异烟肼（INH）和药学有效剂量的以下化合物之一。所述化合物选自以下的化合物组：去甲二氢愈创木酸，反式肉桂醛，大豆黄素，异维生素，山奈酚，二苯甲酰甲基丙三醇，槲皮素，（ - ） - 表没食子儿茶素-3-没食子酸酯，（+） - 柠檬烯，，槲皮素，木犀草素，葡萄糖苷，槲皮素，橙皮苷，橙皮苷，毛林素，（ - ） - 表没食子儿茶素，木犀草素，枸橼酸，肉豆蔻酸乙酯，表儿茶素，（ - ） - 表儿茶素-3-加仑，异亮氨酸，水飞蓟宾，维生素，染料木黄酮，异鼠李素，没食子酸，Diosmin，6-姜醇，（+） - 紫杉醇，黄芩素，原儿茶酸，（+） - 儿茶素，（ - ） - 表儿茶素，Phloridzin，葛根素，Umbelliferone，Brij 58，Brij 76，Brij 35，Tween 20，Tween 80，Tween 40，PEG 2000，PEG 400，Pornornic F68和 PEG 4000.含有药学有效剂量异烟肼（INH）的新型低副作用复合物，（DSF）和/或第三化合物，磷酸双硝基苯酯（BNPP）可以减少异烟肼（INH）诱导的副作用，例如，肝毒性等

124. 发明申请

US20120277196A1 NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS 有权
标题翻译：含有多糖脂肪酸的天然海水来源磷脂及其应用
公开(公告)号：US20120277196A1
公开(公告)日：2012-11-01
申请号：US13545830
申请日：2012-07-10
申请人： Fotini Sampalis
发明人： Fotini Sampalis
IPC分类号： A61K31/683 , A61P9/12 , A61P9/00 , A61P3/06
CPC分类号： A61K31/661 , A23J7/00 , A23K20/158 , A23L33/115 , A23L33/30 , A23V2002/00 , A61K8/553 , A61K9/0053 , A61K9/48 , A61K31/122 , A61K31/353 , A61K31/6615 , A61K31/683 , A61K31/685 , A61K35/612 , A61K2800/522 , A61Q19/00 , C07D407/14 , C07F9/10 , C07F9/117 , C11B1/10 , Y10S514/824 , A23V2250/1846 , A23V2250/1852 , A23V2250/1848 , A23V2250/185 , A23V2250/1868 , A23V2250/187 , A23V2250/70
摘要： A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.
摘要翻译：来自海洋或水生生物的磷脂提取物具有治疗性质。磷脂提取物包含多种磷脂，脂肪酸，金属和新颖的类黄酮。

125. 发明申请

US20120177681A1 Formulation of immunopotentiators 审中-公开
标题翻译：免疫增强剂的配方
公开(公告)号：US20120177681A1
公开(公告)日：2012-07-12
申请号：US13223793
申请日：2011-09-01
申请人： Manmohan Singh , David A.G. Skibinski , Tom Yao-Hsiang Wu , Yongkai Li , Alex Cortez , Xiaoyue Zhang , Yefen Zou , Timothy Z. Hoffman , Jianfeng Pan , Kathy Yue
发明人： Manmohan Singh , David A.G. Skibinski , Tom Yao-Hsiang Wu , Yongkai Li , Alex Cortez , Xiaoyue Zhang , Yefen Zou , Timothy Z. Hoffman , Jianfeng Pan , Kathy Yue
IPC分类号： A61K39/39 , C07F9/6512 , A61K31/675 , A61P31/12 , C07F9/553 , C07F9/645 , A61P37/04 , A61P31/04 , C07F9/6561 , C07F9/38
CPC分类号： C07F9/6561 , A61K31/661 , A61K31/6615 , A61K31/662 , A61K39/02 , A61K39/05 , A61K39/08 , A61K39/092 , A61K39/095 , A61K39/13 , A61K39/145 , A61K39/292 , A61K39/39 , A61K2039/55505 , A61K2039/55511 , C07D471/04 , C07D487/04 , C07F9/645 , C07F9/6512 , C07F9/65583 , C07F9/65616 , Y02A50/466
摘要： Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
摘要翻译：可以将免疫增强剂吸附到不溶性金属盐如铝盐上，以改变其药代动力学，药效学，肌内留置时间和/或免疫刺激作用。修饰免疫增强剂以引入可介导吸附的部分，例如膦酸酯基团。即使以吸附形式递送，这些改性化合物也可以保留或改善其体内免疫活性。

126. 发明申请

US20120129934A1 METHODS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE 有权
标题翻译：治疗阿尔茨海默病类型的敏感性方法
公开(公告)号：US20120129934A1
公开(公告)日：2012-05-24
申请号：US12090342
申请日：2007-08-27
申请人： Dayan Burke Goodenowe
发明人： Dayan Burke Goodenowe
IPC分类号： A61K31/232 , A61P3/06 , A61P25/28
CPC分类号： A61K31/232 , A61K31/661 , A61K31/6615
摘要： The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients.
摘要翻译：本发明涉及老年痴呆型老年痴呆症（SDAT）的诊断，风险评估，预防和治疗。更具体地说，本发明涉及人血清中乙醇胺磷脂的测定。这些分子的亚群在具有病理证实的淀粉样蛋白沉积物的对象中显着改变，而不具有淀粉样蛋白沉积物的受试者和具有痴呆临床表现的受试者与SDAT与非痴呆对照的诊断一致。此外，本发明涉及SDAT的各个阶段的诊断，SDAT症状的早期检测和预防，SDAT的治疗，非SDAT痴呆的鉴别诊断，以及化学或生物治疗可以分解的分子靶标的鉴定设计用于SDAT的治疗干预。本发明还涉及使用分子诊断测定法来指导和选择患有痴呆症的受试者的适当治疗干预的方法。本发明还涉及发现具有SDAT和正常非痴呆患者的临床表现的人之间具有显着不同丰度的小分子或代谢物。

127. 发明授权

US08153676B2 Use of compounds of formula A-R-Xo pharmaceutically acceptable salts thereof for producing a pharmaceutically preparations 有权
标题翻译：式A-R-Xo的药学上可接受的盐在制备药物制剂中的用途
公开(公告)号：US08153676B2
公开(公告)日：2012-04-10
申请号：US12298179
申请日：2007-04-27
申请人： Dieter Mueller-Enoch , Thomas Haehner
发明人： Dieter Mueller-Enoch , Thomas Haehner
IPC分类号： A01N43/50 , A61K31/415 , C07D233/54 , C07D233/60
CPC分类号： A61K31/133 , A61K31/164 , A61K31/19 , A61K31/4164 , A61K31/4172 , A61K31/6615 , A61K31/685
摘要： The invention relates to a compound of formula A-R—X or pharmaceutically acceptable salts thereof which can be used for producing a pharmaceutical preparation suitable for preventing or treating cancerous diseases, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases, hepatic insulin resistance in diabetes mellitus, hepatic damage in Wilson's disease and sideroses and/or ischaemic reperfusion damage, as an antidote against environmental toxins and medicament intoxication in order to extend the resistance time of medicaments in organisms, or for combating toxic side effects in the administration of chemotherapeutics. In the formula R is an aliphatic or aromatic C6- to C40-hydrocarbon radical which has a hydrophilic end A, and X is a radical having at least one free electron pair of a carbon or heteroatom and/or π-electrons.
摘要翻译：本发明涉及式AR-X化合物或其药学上可接受的盐，其可用于制备适于预防或治疗癌性疾病的药物制剂，酒精滥用的病理后果，病毒性肝炎，脂肪性肝炎，急性和慢性胰腺炎，毒性肾脏疾病，糖尿病中的肝胰岛素抵抗，威尔逊氏病和铁血症的肝损伤和/或缺血再灌注损伤，作为对环境毒素和药物中毒的解毒剂，以延长药物在生物体中的抵抗时间，或用于防治有毒副作用化疗药物的治疗效果。在式中，R是具有亲水末端A的脂族或芳族C 6至C 40烃基，X是具有至少一个碳或杂原子和/或pgr-电子的至少一个自由电子对的基团。

128. 发明申请

US20120065172A1 NATURAL MARINE SOURCE PHOSPHOLIPIDS COMPRISING POLYUNSATURATED FATTY ACIDS AND THEIR APPLICATIONS 有权
公开(公告)号：US20120065172A1
公开(公告)日：2012-03-15
申请号：US13280182
申请日：2011-10-24
申请人： Fotini SAMPALIS
发明人： Fotini SAMPALIS
IPC分类号： A61K31/661 , A61P25/16 , A61P25/28 , A61P25/00
CPC分类号： A61K31/661 , A23J7/00 , A23K20/158 , A23L33/115 , A23L33/30 , A23V2002/00 , A61K8/553 , A61K9/0053 , A61K9/48 , A61K31/122 , A61K31/353 , A61K31/6615 , A61K31/683 , A61K31/685 , A61K35/612 , A61K2800/522 , A61Q19/00 , C07D407/14 , C07F9/10 , C07F9/117 , C11B1/10 , Y10S514/824 , A23V2250/1846 , A23V2250/1852 , A23V2250/1848 , A23V2250/185 , A23V2250/1868 , A23V2250/187 , A23V2250/70
摘要： A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

129. 发明申请

US20120003327A1 METHOD OF REDUCING MULTI-DRUG RESISTANCE USING INOSITOL TRIPYROPHOSPHATE 审中-公开
标题翻译：使用磷酸二氢铁磷酸盐降低多药耐药性的方法
公开(公告)号：US20120003327A1
公开(公告)日：2012-01-05
申请号：US13033363
申请日：2011-02-23
申请人： Yves Claude NICOLAU , Jean-Marie LEHN , Claudine KIEDA
发明人： Yves Claude NICOLAU , Jean-Marie LEHN , Claudine KIEDA
IPC分类号： A61K31/6615 , A61P35/00 , A61K33/24
CPC分类号： A61K31/6615 , A61K31/282 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/665 , A61K31/7068 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.
摘要翻译：肌醇三磷酸（ITPP）导致肿瘤血管系统的正常化，并且当在部分血管形成后施用第二化学治疗剂时，是特别有效的癌症治疗。 ITPP也单独或组合治疗多重耐药性癌症。 ITPP也可用于减少抗癌活性所需的第二化疗药物的量。此外，ITPP增强免疫反应并治疗过度增殖性疾病。

130. 发明授权

US07972595B2 Methods and compositions for protecting and treating at least one muscarinic receptor from dysfunction not resulting from oxidative stress, toxic actions of metals or infectious agents by administering a pyrophosphate analog 有权
标题翻译：用于保护和治疗至少一种毒蕈碱受体的方法和组合物不是由氧化应激引起的功能障碍，金属或感染因子的毒性作用，通过施用焦磷酸盐类似物
公开(公告)号：US07972595B2
公开(公告)日：2011-07-05
申请号：US11191901
申请日：2005-07-28
申请人： William H. Frey, II , John Randall Fawcett
发明人： William H. Frey, II , John Randall Fawcett
IPC分类号： A61K38/44 , A61K31/70
CPC分类号： A61K31/6615 , A61K31/352 , A61K31/409 , A61K31/66 , A61K31/661 , A61K31/662 , A61K31/663 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/7084 , A61K31/7105 , A61K45/06 , A61K2300/00
摘要： Methods and compositions for protecting and treating a muscarinic receptor in a subject in need thereof from dysfunction not resulting from oxidative stress, toxic actions of metals or metal ions, or infectious agents by administering a pyrophosphate analog.
摘要翻译：用于保护和治疗有需要的受试者的毒蕈碱受体的方法和组合物，其不是由氧化应激引起的功能障碍，金属或金属离子的毒性作用或通过施用焦磷酸酯类似物的感染剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式